DEFA14A: ESSA Pharma Amends XenoTherapeutics Deal, Lowers Cash Payout

ESSA Pharma Inc. has amended its business combination agreement with XenoTherapeutics, reducing the upfront cash payment to shareholders and introducing a contingent value right.

Summary

• ESSA Pharma Inc. amended its Business Combination Agreement with XenoTherapeutics, Inc. and XOMA Royalty Corporation.
• Shareholders are now expected to receive approximately US$0.12 per Common Share in cash at closing, in addition to the US$1.69 per share already distributed.
• This new cash payment of US$0.12 is lower than the originally estimated aggregate distribution of US$1.91 per share (before CVRs).
• Shareholders will also receive one non-transferable Contingent Value Right (CVR) per Common Share, representing the right to receive up to approximately US$0.14 per CVR.
• The potential CVR payment totals up to US$6.7 million in aggregate, contingent on the outcome of certain liabilities.
• The changes were made due to potential liabilities, associated expenses, and updated estimates of ESSA's cash balance at closing.
• The special meeting for shareholders, optionholders, and warrantholders has been further adjourned from September 29, 2025, to October 3, 2025.

Sentiment

Score: 3

Explanation: The reduction in the guaranteed cash payout to shareholders and the introduction of a contingent value right for a portion of the consideration, driven by 'potential liabilities and associated expenses,' indicates a less favorable outcome for shareholders than initially anticipated. The further adjournment of the special meeting also adds to uncertainty.

Positives

• The transaction with XenoTherapeutics and XOMA Royalty is proceeding, indicating continued strategic direction.
• Shareholders have already received an initial cash distribution of approximately US$1.69 per Common Share.
• The Contingent Value Right (CVR) offers potential for additional payments of up to US$0.14 per CVR, totaling up to US$6.7 million, depending on contingent liabilities.

Negatives

• The expected cash payment at closing has been reduced from an estimated US$1.91 (aggregate distribution) to US$0.12 per Common Share (in addition to the US$1.69 already distributed), meaning the total guaranteed cash is lower than initially projected.
• A portion of the previously estimated aggregate distribution is now tied to a contingent value right (CVR), making it uncertain.
• The CVR payments are non-transferable, limiting liquidity for shareholders.
• The amendment was driven by potential liabilities and associated expenses, indicating unforeseen financial challenges.
• The special meeting has been further adjourned, potentially prolonging the transaction timeline and creating uncertainty.

Risks

• Completion of the transaction on anticipated terms and timing, including obtaining required securityholder, regulatory, and court approvals, and satisfaction of other conditions.
• The potential for the date of the Special Meeting to change again.
• Potential litigation relating to the transaction that could be instituted by or against ESSA, Xeno, XOMA Royalty, or their respective directors or officers.
• Potential exposure or liability relating to the due bill communication matter that occurred on August 25, 2025.
• Disruptions from the transaction harming ESSA's business, including current plans and operations.
• Ability to retain and hire key personnel.
• Potential adverse reactions or changes to business relationships resulting from the announcement or completion of the transaction.
• Continued availability of capital and financing and rating agency actions.
• Legislative, regulatory, and economic developments affecting ESSA's business.
• Accuracy of ESSA's financial projections.
• General business, market, and economic conditions.
• Restrictions during the pendency of the transaction that may impact ESSA's ability to pursue certain business opportunities or strategic transactions.
• Unpredictability and severity of catastrophic events, including acts of terrorism, pandemics, outbreaks of war or hostilities.
• Significant transaction costs associated with the transaction.
• The possibility that the transaction may be more expensive to complete than anticipated due to unexpected factors or events.
• Competitive responses to the transaction.
• The CVRs are highly speculative, and there is no assurance that holders will receive any payments under the CVR agreement.

Future Outlook

The company anticipates the completion of the business combination transaction with XenoTherapeutics, Inc. following shareholder approval at the reconvened Special Meeting on October 3, 2025, and subsequent court approval on October 7, 2025. The future CVR payments are contingent on the resolution of specified liabilities, and there is no assurance that holders will receive any payments.

Management Comments

• ESSA and Xeno are making this change in light of potential liabilities, associated expenses and the latest estimates of the Company's expected cash balance at closing.
• The additional adjournment will allow time for shareholders to consider and approve the Amended Agreement.

Industry Context

This amendment reflects common challenges in biotechnology mergers, where initial financial estimates can shift due to unforeseen liabilities or changes in cash flow. The use of Contingent Value Rights (CVRs) is a frequent mechanism in biotech M&A to bridge valuation gaps and manage risks associated with contingent outcomes, such as litigation or clinical milestones, allowing a deal to proceed despite uncertainties.

Legal Proceedings

• Company Litigation: Any proceeding against or involving the Company and its directors/officers included in the Disclosure Letter or existing/arising within 18 months post-closing from facts/circumstances at Effective Time (excluding Purchaser/Parent initiated proceedings).
• Potential Contingent Claim Liability: Any proceeding against or involving the Company and its directors/officers arising from public disclosures on August 14, 2025, and August 25, 2025, regarding the period when Common Shares traded with due bills on Nasdaq (excluding Purchaser/Parent initiated proceedings).

Stakeholder Impact

• Shareholders: Will receive less guaranteed cash upfront and a portion of their consideration is now contingent and non-transferable, introducing risk and reducing liquidity.
• Management/Directors: Potential for litigation related to the transaction and past disclosures, with defense costs potentially impacting CVR proceeds.

Next Steps

• ESSA will file supplemental proxy materials reflecting the Amendment.
• ESSA intends to apply to the Supreme Court of British Columbia to amend the interim order for a new meeting date and related deadlines.
• The Special Meeting will reconvene on October 3, 2025, for shareholders to consider and approve the Amended Agreement.
• A new Court hearing for approval of the Arrangement is scheduled for October 7, 2025.
• Resolution of Company Litigation and Potential Contingent Claim Liabilities will determine CVR payments.

Key Dates

Recommendation

The amendment significantly reduces the guaranteed cash payout to shareholders and converts a portion of the expected value into a contingent value right (CVR) that is non-transferable and dependent on the outcome of potential liabilities. This introduces substantial uncertainty and downside risk, making the deal less attractive than initially presented. The reasons for the change—'potential liabilities, associated expenses, and the latest estimates of the Company's expected cash balance'—suggest underlying issues that further erode shareholder value. For a seasoned investor, this shift from a more certain cash distribution to a lower cash amount plus a speculative CVR, coupled with transaction delays, signals a deterioration of the deal's terms and warrants a 'sell' recommendation to mitigate further potential losses or opportunity costs.

Keywords

ESSA Pharma, XenoTherapeutics, XOMA Royalty, Business Combination Agreement, Merger, Acquisition, Contingent Value Right, CVR, Shareholder Payout, SEC Filing, Biotechnology, Prostate Cancer, Xenotransplantation, Corporate Action